Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer (NCT06795009)
Phase I/IB Study of Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.
Who can join: Review the eligibility criteria below.
Location: University of California, San Francisco — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- University of California, San Francisco — San Francisco, California
- Washington University School of Medicine — St Louis, Missouri
- University of New Mexico — Albuquerque, New Mexico
- University of Oklahoma — Oklahoma City, Oklahoma
📞 Contact the Study Coordinator
Phone: (314) 362-3181
Email: mutchd@wustl.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Uterine Cancer
- AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma — Boston, Massachusetts
- Insights Into Participating in Studies for Uterine Cancer — San Francisco, California
- Investigations of Reproductive Cancers in Women — Birmingham, Alabama
- [18F]FES PET/.CT in Uterine Cancer — Philadelphia, Pennsylvania
- Trans-Rectal Ultrasound of the Female Pelvis for Real-Time MRI-US Fusion Based Needle Tracking — Durham, North Carolina
Explore by condition: All Uterine Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.